Health · 2 views
Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD).
AI Summary
New research examines the potential benefits and risks of sodium‑glucose cotransporter 2 (SGLT2) inhibitors in adults aged 80 years or older who have chronic kidney disease. The findings are slated for presentation at ASN Kidney Week 2026, scheduled for October 22–25.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Tovecimig-Based Doublet Boosts Response and PFS in Advanced Biliary Tract CancerContinue reading
- Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast CancerContinue reading
- Patient Death Reported in Multiple Sclerosis CAR-T StudyContinue reading
- Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA NephropathyContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow